Warning letter
Beijing Xinggu Lvsan Technology Co., Ltd. Formerly known as Beijing Lvsan Technology Co., Ltd.: warning letter of Oct 5, 2022
FDA warning letter 633904 · Center for Drug Evaluation and Research | CDER
Key facts
| Reference number | 633904 |
|---|---|
| Company | Beijing Xinggu Lvsan Technology Co., Ltd. Formerly known as Beijing Lvsan Technology Co., Ltd. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug/Misbranded |
| Issue date | Oct 5, 2022 |
| Posted date | Oct 18, 2022 |
| Issuing office | Center for Drug Evaluation and Research | CDER |
| Product type | Drugs |
| CFR sections cited | 211.84(d)(1), 201.66(c), 211.165(b), 201.66, 201.128, 211.22, 211.34, 330, 211.67(b), 211.100(a) |
| Inspection city | Beijing |
| Inspection start date | Apr 11, 2022 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: